However, one study demonstrated that CD39lo Tregs could not alter GVHD, but this effect could be overcome by the addition of IL-2 [111], indicating a central role for this cytokine in the promotion of donor Tregs to prevent GVHD. The gene discussed is IL2; the disease is graft versus host disease.